Logo Image
|Videos|August 8, 2019

Treatment and Prevention of Influenza

Leslie Tari, PhD, discusses the treatment and prevention of influenza.

Segment Description: Leslie Tari, PhD, senior vice president of research at Cidara Therapeutics, discusses the treatment and prevention of influenza.

Interview transcript (modified slightly for readability):

Dr. Tari: "There are 2 problems with influenza. There are seasonal vaccines, which have limited effectiveness. Over the past decade the effectiveness of the influenza vaccine from the CDC website has varied from between 10 to about 60% and there are populations—elderly, very young, and immocompromised populations—where the vaccine efficacy is even lower, so for protection and prevention of flu there's still a lot of work to be done to address that unmet need. On the treatment side, all of the antivirals that are currently approved for flu have a limited window where they could be administered and still remain effective, so right now that's 48 hours from onset of symptoms. There are still significant challenges on the prevention and the treatment space for flu."

The study, “Cloudbreak: A Novel Approach for the Treatment and Prevention of Influenza Virus,” was presented in an oral session on Monday, April 15, 2019, at ECCMID 2019 in Amsterdam, the Netherlands.

Related to this article

View more
REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.
Read more
GSK's mRNA Influenza Vaccine Moves to Phase 3 Trial
GSK's mRNA Influenza Vaccine Moves to Phase 3 Trial
GSK will advance its investigational mRNA seasonal flu vaccine candidate, which targets both hemagglutinin and neuraminidase, into a phase 3 trial in September 2026 after the shot outperformed licensed flu vaccines in a phase 2 study.
Read more
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Read more